Revolutionizing treatment
decisions for coronary
artery disease.
Quick, non-invasive,
wire-free 3D FFR guidance.
Introducing the Cathworks
Confident answers for coronary artery disease.
Transform routine angiograms into objective multi-vessel physiologic, and anatomic insights, giving you the information you need to optimize PCI treatment decisions.
Elevate your practice with the proven benefits of FFR.
FFRangio delivers highly accurate multi-vessel FFR results without the need for an invasive pressure wire or hyperemic stimulus, making important FFR benefits practical for more patients.
FAME study: FFR-guided PCI improves outcomes and saves cost compared to angiography-guided PCI.
30%
Reduction in stents per patient*
28%
Relative Reduction in 1-year clinical events*
14%
Reduction in costs at 1-year**
Physician Perspectives
CVIT 2021: Dr. Rahul P. Sharma, Interventional Cardiologist and Director of Structural Interventions at Stanford Medical Center, shares his experience with FFRangio, including important clinical evidence and the benefits of FFRangio for routine clinical practice.
Watch the dr. Sharma CVIT PresentationFFRangio in Clinical Practice
Dr. Rahul P. Sharma
Stanford Healthcare
FFRangio Compared to FFR Clinical Data
Dr. William F. Fearon
Stanford University Medical Center, California
Applicability of FFRangio in Serial Lesions Diffuse Disease
Dr. Carlos Collet Bortone
the Cardiovascular Center OLV AALST, Belgium
FFRangio in Routine Clinical Practice US Experience
Dr. Rahul P. Sharma
Stanford University Medical Center, California
“FFRangio has the potential to eventually replace wire-based FFR measurement and substantially increase physiological coronary lesion assessment in the catheterization laboratory, thereby leading to improved patient outcomes”
View Clinical StudiesFAST-FFR Trial: Fearon WF, et al. Circ. September 2018. 10.1161/CIRCULATIONAHA.118.037350.
Events
TCT 2019
San Francisco, CA
Room 203,Level 2 Moscone South,
Moscone Center
Regulatory Status
The CathWorks FFRangio™ System has received United States 510(k) clearance, Europe CE approval, Israel Amar approval, and Japan PMDA approval.
*Tonino et al. N Engl J Med. January 15, 2009; 360:213-224;
**Fearon et al. Circulation. 2010;122:2545-2550;